ASN Report 2017

55 ASN report on the state of nuclear safety and radiation protection in France in 2017 Chapter 01  - Nuclear activities: ionising radiation and health and environmental risks and thirty one people were subject to monitoring of lens of the eye exposure. The maximum dose recorded is 21.8 mSv and concerns the area of medical applications. This value should be compared with the new regulatory dose limit for the lens of the eye: cumulative value of 100 mSv over five years, without exceeding 50 mSv in a given year (20 mSv/year as from 2023). The results of dosimetricmonitoring of worker external exposure in 2016 published by IRSN in June 2017 showon the whole that the prevention system introduced in facilities where sources of ionising radiation are used is effective, because for 96% of the population monitored, the annual dose remained lower than 1 mSv (effective annual dose limit for the public as a result of nuclear activities). Exceeding the regulatory limit values remains exceptional. 3.1.2 Worker exposure to TENORM (Technologically Enhanced Naturally Occurring Radioactive Materials) Occupational exposure to TENORM is the result either of the ingestion of dust containing large amounts of radionuclides (phosphates, metal ore), or of the inhalation of radon formed by uranium decay (poorly ventilated warehouses, thermal baths) or of external exposure due to process deposits (scale forming in piping for example). The results of the studies carried out in France since 2005 and published by ASN in January 2010, as well as the studies received since then, show that 85% of the doses received by workers in the industries concerned remained below 1 mSv/year. The industrial sectors in which worker exposure is liable to exceed 1mSv/year are the following: titanium ore processing, heating systems and recycling of refractory ceramics, maintenance of parts comprising thorium alloys in the aeronautical sector, chemical processing of zircon ore, mechanical transformation and utilisation of zircon and processing of rare earths. The trends observed and published in 2010 are still valid in view of the files received up to 2015. No new study was transmitted in 2016. DIAGRAM 3: Evolution of number of workers monitored, with an annual effective dose in excess of 20 mSv from 1996 to 2016 0 100 200 300 400 500 600 700 800 900 1,000 2016 2015 2014 2013 2012 2011 2009 2010 2007 2008 2005 2006 2003 2004 2001 2002 1999 2000 1997 1998 1996 905 340 322 177 69 112 79 100 51 40 26 22 16 14 14 8 8 1 2 8 9 Source: IRSN DIAGRAM 2: Monitored population and collective dose trends, from 1996 to 2016 2016 2015 2014 2013 2004 2003 2002 2001 2000 2009 2008 2007 2012 2011 2010 2006 2005 1999 1998 1997 1996 0 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 0 20 40 60 80 100 120 140 119.4 121.5 90.6 90.8 87.5 74.5 67.2 52.1 56.9 59.6 65.7 62.4 64.3 63.2 61.9 68.5 70.5 63.7 64.8 56.3 62.4 Source: IRSN Number of persons monitored Collective dose (man-Sv) Collective dose (man-Sv) Number of persons monitored